Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: COX7B

Gene summary for COX7B

Gene summary.

Gene information	Species	Human
	Gene symbol	COX7B
	Gene ID	1349
	Gene name	cytochrome c oxidase subunit 7B
	Gene Alias	APLCC
	Cytomap	Xq21.1
	Gene Type	protein-coding
	GO ID	GO:0006091
	UniProtAcc	P24311

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
1349	COX7B	GSM4909281	Human	Breast	IDC	1.59e-32	5.33e-01	0.21
1349	COX7B	GSM4909282	Human	Breast	IDC	1.97e-20	4.14e-01	-0.0288
1349	COX7B	GSM4909286	Human	Breast	IDC	2.41e-09	-2.81e-01	0.1081
1349	COX7B	GSM4909287	Human	Breast	IDC	1.48e-14	3.71e-01	0.2057
1349	COX7B	GSM4909288	Human	Breast	IDC	3.11e-07	2.40e-01	0.0988
1349	COX7B	GSM4909290	Human	Breast	IDC	3.73e-11	4.13e-01	0.2096
1349	COX7B	GSM4909294	Human	Breast	IDC	6.48e-42	4.68e-01	0.2022
1349	COX7B	GSM4909296	Human	Breast	IDC	8.33e-18	8.38e-02	0.1524
1349	COX7B	GSM4909297	Human	Breast	IDC	2.22e-24	-1.91e-01	0.1517
1349	COX7B	GSM4909301	Human	Breast	IDC	1.27e-02	9.27e-02	0.1577
1349	COX7B	GSM4909306	Human	Breast	IDC	8.59e-10	3.31e-01	0.1564
1349	COX7B	GSM4909311	Human	Breast	IDC	9.91e-55	-3.25e-01	0.1534
1349	COX7B	GSM4909312	Human	Breast	IDC	4.52e-16	-2.18e-01	0.1552
1349	COX7B	GSM4909313	Human	Breast	IDC	4.81e-11	-4.02e-01	0.0391
1349	COX7B	GSM4909315	Human	Breast	IDC	6.74e-04	1.83e-01	0.21
1349	COX7B	GSM4909316	Human	Breast	IDC	1.85e-11	3.36e-01	0.21
1349	COX7B	GSM4909318	Human	Breast	IDC	6.93e-06	2.02e-01	0.2031
1349	COX7B	GSM4909319	Human	Breast	IDC	2.97e-63	-5.07e-01	0.1563
1349	COX7B	GSM4909320	Human	Breast	IDC	1.04e-06	-1.07e-01	0.1575
1349	COX7B	GSM4909321	Human	Breast	IDC	1.55e-22	-2.94e-01	0.1559

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00460349	Breast	Precancer	ATP metabolic process	82/1080	277/18723	1.94e-36	5.19e-33	82
GO:00061199	Breast	Precancer	oxidative phosphorylation	53/1080	141/18723	1.15e-29	2.04e-26	53
GO:00090608	Breast	Precancer	aerobic respiration	58/1080	189/18723	5.69e-27	7.62e-24	58
GO:00060918	Breast	Precancer	generation of precursor metabolites and energy	94/1080	490/18723	1.54e-25	1.64e-22	94
GO:00453338	Breast	Precancer	cellular respiration	59/1080	230/18723	5.97e-23	5.32e-20	59
GO:00159808	Breast	Precancer	energy derivation by oxidation of organic compounds	70/1080	318/18723	8.33e-23	6.37e-20	70
GO:00229008	Breast	Precancer	electron transport chain	42/1080	175/18723	1.37e-15	4.59e-13	42
GO:19026008	Breast	Precancer	proton transmembrane transport	39/1080	157/18723	4.18e-15	1.18e-12	39
GO:004603414	Breast	IDC	ATP metabolic process	85/1434	277/18723	6.42e-30	1.82e-26	85
GO:000611913	Breast	IDC	oxidative phosphorylation	56/1434	141/18723	1.87e-26	3.53e-23	56
GO:000906013	Breast	IDC	aerobic respiration	61/1434	189/18723	4.42e-23	6.27e-20	61
GO:000609113	Breast	IDC	generation of precursor metabolites and energy	103/1434	490/18723	1.53e-21	1.74e-18	103
GO:004533313	Breast	IDC	cellular respiration	62/1434	230/18723	5.98e-19	4.25e-16	62
GO:001598013	Breast	IDC	energy derivation by oxidation of organic compounds	73/1434	318/18723	8.70e-18	3.80e-15	73
GO:002290013	Breast	IDC	electron transport chain	51/1434	175/18723	2.23e-17	8.43e-15	51
GO:190260012	Breast	IDC	proton transmembrane transport	40/1434	157/18723	7.34e-12	1.34e-09	40
GO:004603424	Breast	DCIS	ATP metabolic process	85/1390	277/18723	6.79e-31	1.92e-27	85
GO:000611923	Breast	DCIS	oxidative phosphorylation	56/1390	141/18723	3.89e-27	7.34e-24	56
GO:000906023	Breast	DCIS	aerobic respiration	61/1390	189/18723	8.72e-24	1.23e-20	61
GO:000609123	Breast	DCIS	generation of precursor metabolites and energy	103/1390	490/18723	1.46e-22	1.65e-19	103

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0501228	Prostate	BPH	Parkinson disease	143/1718	266/8465	1.19e-34	3.94e-32	2.44e-32	143
hsa0502026	Prostate	BPH	Prion disease	141/1718	273/8465	1.11e-31	1.23e-29	7.58e-30	141
hsa0501626	Prostate	BPH	Huntington disease	149/1718	306/8465	8.82e-30	7.27e-28	4.50e-28	149
hsa0019026	Prostate	BPH	Oxidative phosphorylation	83/1718	134/8465	3.75e-26	2.48e-24	1.53e-24	83
hsa0520828	Prostate	BPH	Chemical carcinogenesis - reactive oxygen species	114/1718	223/8465	3.05e-25	1.44e-23	8.91e-24	114
hsa0501026	Prostate	BPH	Alzheimer disease	165/1718	384/8465	4.03e-25	1.66e-23	1.03e-23	165
hsa0541527	Prostate	BPH	Diabetic cardiomyopathy	102/1718	203/8465	6.06e-22	2.00e-20	1.24e-20	102
hsa0501426	Prostate	BPH	Amyotrophic lateral sclerosis	151/1718	364/8465	3.37e-21	1.01e-19	6.25e-20	151
hsa0471428	Prostate	BPH	Thermogenesis	110/1718	232/8465	5.16e-21	1.42e-19	8.78e-20	110
hsa0493226	Prostate	BPH	Non-alcoholic fatty liver disease	83/1718	155/8465	2.49e-20	6.32e-19	3.91e-19	83
hsa0502226	Prostate	BPH	Pathways of neurodegeneration - multiple diseases	180/1718	476/8465	7.70e-20	1.81e-18	1.12e-18	180
hsa0426024	Prostate	BPH	Cardiac muscle contraction	29/1718	87/8465	2.91e-03	1.12e-02	6.91e-03	29
hsa05012112	Prostate	BPH	Parkinson disease	143/1718	266/8465	1.19e-34	3.94e-32	2.44e-32	143
hsa05020111	Prostate	BPH	Prion disease	141/1718	273/8465	1.11e-31	1.23e-29	7.58e-30	141
hsa05016111	Prostate	BPH	Huntington disease	149/1718	306/8465	8.82e-30	7.27e-28	4.50e-28	149
hsa00190111	Prostate	BPH	Oxidative phosphorylation	83/1718	134/8465	3.75e-26	2.48e-24	1.53e-24	83
hsa05208113	Prostate	BPH	Chemical carcinogenesis - reactive oxygen species	114/1718	223/8465	3.05e-25	1.44e-23	8.91e-24	114
hsa05010111	Prostate	BPH	Alzheimer disease	165/1718	384/8465	4.03e-25	1.66e-23	1.03e-23	165
hsa05415112	Prostate	BPH	Diabetic cardiomyopathy	102/1718	203/8465	6.06e-22	2.00e-20	1.24e-20	102
hsa05014111	Prostate	BPH	Amyotrophic lateral sclerosis	151/1718	364/8465	3.37e-21	1.01e-19	6.25e-20	151

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

COX7B

SNV

Missense_Mutation

novel

c.209N>C

p.Gly70Ala

p.G70A

P24311

protein_coding

deleterious(0.03)

probably_damaging(0.945)

TCGA-AR-A5QP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

COX7B

SNV

Missense_Mutation

novel

c.32G>A

p.Arg11His

p.R11H

P24311

protein_coding

tolerated(0.81)

benign(0.001)

TCGA-A5-A1OF-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

COX7B

SNV

Missense_Mutation

novel

c.122N>C

p.Val41Ala

p.V41A

P24311

protein_coding

deleterious(0)

possibly_damaging(0.569)

TCGA-AJ-A23O-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

COX7B

SNV

Missense_Mutation

c.34C>A

p.Leu12Ile

p.L12I

P24311

protein_coding

deleterious(0.04)

probably_damaging(0.934)

TCGA-AP-A051-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

COX7B

SNV

Missense_Mutation

rs782772132

c.169N>T

p.Ala57Ser

p.A57S

P24311

protein_coding

tolerated(0.31)

possibly_damaging(0.533)

TCGA-AP-A1E0-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

paclitaxel

COX7B

SNV

Missense_Mutation

novel

c.91N>G

p.Pro31Ala

p.P31A

P24311

protein_coding

deleterious(0.04)

possibly_damaging(0.665)

TCGA-AX-A06F-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

COX7B

SNV

Missense_Mutation

c.211N>G

p.Arg71Gly

p.R71G

P24311

protein_coding

deleterious(0)

possibly_damaging(0.899)

TCGA-B5-A0K9-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

COX7B

SNV

Missense_Mutation

c.119N>T

p.Ala40Val

p.A40V

P24311

protein_coding

tolerated(0.35)

benign(0.015)

TCGA-B5-A1MY-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

COX7B

SNV

Missense_Mutation

c.74G>A

p.Ser25Asn

p.S25N

P24311

protein_coding

tolerated(0.22)

benign(0.037)

TCGA-EO-A3AY-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

COX7B

SNV

Missense_Mutation

rs782685682

c.86N>A

p.Arg29His

p.R29H

P24311

protein_coding

tolerated(0.82)

benign(0.007)

TCGA-EY-A215-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1